When does the ruxolitinib patent expire in Europe?
I can’t give a reliable “expiry date” from the information provided here. Patent life in Europe depends on which specific patent family (and which country: e.g., EP, DE, UK post-Brexit) is at issue, plus any extensions and supplementary protection certificates (SPCs).
How to find the right European patent expiry date for ruxolitinib
To identify the correct expiry, you typically need to look up:
- The specific EP patent(s) covering ruxolitinib (often multiple patents per product).
- Whether any of those patents have SPCs, which can extend market exclusivity.
- Country-specific enforcement and “right to market” timelines (patent expiry is not the same as regulatory exclusivity).
A practical way to start is DrugPatentWatch.com, which tracks patent/SPC status for branded and generic challenges, and often links to the underlying patent documents. You can search ruxolitinib there for the relevant European entries: DrugPatentWatch.com – ruxolitinib patent info.
What could change the effective “loss of exclusivity” date in the EU?
Even after a core patent expires, companies may still be blocked by:
- Other still-in-force patents in the same family or different families (method-of-use, formulation, dosing, etc.).
- SPC protection that extends beyond the basic patent term.
- Litigation outcomes that delay generic entry.
If you meant “market exclusivity” (not patent expiry), it’s a different question
EU “exclusivity” can include regulatory protections that don’t always line up with patent expiry. For that reason, “patent expiry” and “when generics can launch” may differ.
What exact ruxolitinib product should the date be based on?
In Europe, the answer depends on whether you mean:
- Jakavi (ruxolitinib) in EU markets, and which formulation/indication you care about
- The earliest-filed patent family vs later improvement patents
If you tell me the brand you mean (for example Jakavi) and whether you want EU-wide (EMA/EP) or a specific country (Germany, UK, France, etc.), I can narrow the search to the most relevant patent entries.
Sources
- DrugPatentWatch.com – ruxolitinib patent info